Core Insights - Walgreens (WBA) faced a challenging year in 2024, but its first-quarter results exceeded expectations, leading to initial optimism for 2025 [2][6] - Despite the positive results, analysts remain cautious, with most maintaining "hold" or "sell" ratings on the stock [6] - A recent lawsuit from the Department of Justice has negatively impacted Walgreens' stock, contributing to a decline of over 9% [2][6] Analyst Ratings - Among eight analysts covering Walgreens, four have issued "hold" ratings, three rated it "sell," and only one gave a "buy" rating, with an average price target of $10.81, slightly below the recent closing price of $11.37 [3] - Jefferies and Deutsche Bank analysts have maintained "hold" ratings, expressing the need for more positive data points before expecting a significant turnaround [4] Business Challenges - Analysts highlighted that despite cost-cutting measures, including the closure of hundreds of underperforming stores, Walgreens' retail pharmacy business is likely to continue facing challenges [5] - The new lawsuit from the DOJ adds regulatory risk to Walgreens' already difficult retail environment, as acknowledged by the CEO during the earnings call [5]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Walgreens Boots Alliance, Inc. due to allegations of materially misleading business information [1] Group 1: Legal Investigation - The investigation is prompted by allegations that Walgreens knowingly filled millions of prescriptions for controlled substances without a legitimate medical purpose from August 2012 to the present [3] - Following the announcement from the U.S. Department of Justice, Walgreens' stock price fell in aftermarket trading on January 17, 2025 [3] Group 2: Class Action Details - Investors who purchased Walgreens securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2] - Interested investors can join the class action by submitting a form or contacting the Rosen Law Firm directly [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4] - The firm has been ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 [4]

Key TakeawaysThe S&P 500 added 0.9% on Tuesday, Jan. 21, the first day of trading following President Donald Trump's return to the White House.Oracle stock surged following reports that the software giant would participate in a massive joint venture to build out AI infrastructure in the U.S.Walgreens shares plunged as the Justice Department filed a lawsuit claiming the pharmacy chain had dispensed prescriptions with no legitimate medical basis. Major U.S. equities indexes advanced as the markets kicked off ...

Key TakeawaysWalgreens Boots Alliance shares tumbled Tuesday after Department of Justice allegations that its pharmacies dispensed prescriptions with no legitimate medical reasoning.The DOJ filed a lawsuit late last week accusing the pharmacy of handing out "millions of unlawful prescriptions" for dangerous opioids, among other drugs.Walgreens said the government is trying to put its pharmacists in a "no-win situation." Walgreens Boots Alliance (WBA) shares sank Tuesday, the first day of trading since the D ...

Shares of Walgreens Boots Alliance (WBA -13.61%) pulled back today after the company again ran into trouble with regulators.On Friday, the Department of Justice (DOJ) filed a lawsuit against Walgreens, alleging that it dispensed "millions of unlawful prescriptions."As of 10:26 a.m. ET, the stock was down 12.7% on the news. Walgreens gets another red flagWalgreens already made a multibillion-dollar settlement over opioid prescriptions two years ago. It agreed to pay $5.7 billion over 15 years, and now it cou ...

Last week, the U.S. Department of Justice filed a civil complaint against Walgreens Boots Alliance Inc WBA and its subsidiaries, alleging widespread violations of the Controlled Substances Act (CSA) and False Claims Act (FCA).In a statement, Walgreens said, “We are asking the court to clarify the responsibilities of pharmacies and pharmacists and to protect against the government’s attempt to enforce arbitrary “rules” that do not appear in any law or regulation and never went through any official rulemaking ...

Core Viewpoint - The law firm Bronstein, Gewirtz & Grossman, LLC has announced an investigation into Walgreens Boots Alliance, Inc. (WBA) and is encouraging stockholders to learn more about the investigation [1] Group 1 - The investigation is focused on potential violations of federal securities laws by Walgreens Boots Alliance, Inc. [1] - Stockholders are urged to contact the law firm for more information regarding the investigation [1] - The announcement indicates that the investigation may relate to the company's financial disclosures and business practices [1]

Bronstein, Gewirtz & Grossman, LLC Encourages Walgreens Boots Alliance, Inc. (WBA) Investors to Inquire about Securities Investigation ...

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Walgreens Boots Alliance, Inc. Investors to Inquire About Securities Class Action Investigation - WBA ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...